

# **Chapter 16**

## **Organisational Matters**



## 16.1. IFCC Office

The IFCC Office is the unit of the IFCC responsible for carrying out, under the direction of the EB and in conjunction with Division and Committee members, the administrative and communication activities of the Federation. The IFCC Office reports to the EB through the Secretary.

The IFCC Office is the administrative centre of the IFCC and maintains the Archives of the organisation. The IFCC Office is responsible for day-to-day financial operations such as: billing members for dues, controlling of claims, accounting of income and expenditures, quarterly budget report to the EB. It is also responsible for all contacts with Member societies for official communications sent to the Members by the Executive Board and its officers. The IFCC Office is responsible for most of the daily and organisational matters and is the point of contact for all IFCC activities. The IFCC Office has responsibilities for supporting the Executive Board, Division Executives and Committees, for maintaining the IFCC website and for all relevant documentation. The IFCC Office also supports the organisation of some IFCC Conferences. The IFCC Office is staffed by three employees, and other staff as required.

The IFCC Office is located within the premises of MZ Congressi, Milan, Italy, which is the professional congress organizer (PCO) for the IFCC.

### **The IFCC Office address is:**

Via Carlo Farini 81

20159 Milan, Italy

E-mail: [ifcc@ifcc.org](mailto:ifcc@ifcc.org)

IFCC website: [www.ifcc.org](http://www.ifcc.org)

## 16.3. Nominations Committee

### 16.3.1. Summary

The Executive Board creates an ad hoc Nominations Committee (NC) and appoints the Chair. This occurs every third year with the Committee being appointed two years prior to the next Council meeting. It is the responsibility of the NC to invite, receive and process nominations for the next Executive Board. To do so, the NC solicits suggestions for candidates for each position on the Executive Board (except the Past-President and Corporate Representative), from Full Members of the IFCC and from key individuals within the management structure of the IFCC. The NC then recommends a slate of candidates consisting of one or more persons for each vacancy. Also, the candidates must be nominated by the Association of the country where the candidate works, and not by another Association of which they are a member.

The Nominations Committee will conduct this activity independent of the current Executive Board (whose members may be seeking re-election). Also, it will establish an appropriate deadline by which all nominations must be received. The NC does not function as a “Search Committee” and has no long-term role in “human resource development” or “succession planning”.

The election for the new EB will be conducted by electronic ballot and the result will be announced at the meeting of Council prior to the IFCC WorldLab 2023 meeting in Rome.

### 16.3.2. Members

<b>Name</b>	<b>Position</b>	<b>Country</b>	<b>Term</b>	<b>Time in Office</b>
L. Lai	Chair	MY	1 <sup>st</sup>	2021 05 - 2023 12
G. Beastall	Past Chair	UK	1 <sup>st</sup>	2021 01 - 2023 12
<i>AFCB Regional Federation</i>				
O. Najjar	Representative	PS	2 <sup>nd</sup>	2021 06 - 2023 12
<i>AFCC Regional Federation</i>				
A. Amayo	Representative	KE	2 <sup>nd</sup>	2021 06 - 2023 12
<i>APFCB Regional Federation</i>				
E. Hoyaranda	Representative	ID	2 <sup>nd</sup>	2021 06 - 2023 12
<i>COLABIOCLI Regional Federation</i>				
R. Sierra-Amor	Representative	MX	1 <sup>st</sup>	2021 06 - 2023 12
<i>EFLM Regional Federation</i>				
K. Kohse	Representative	DE	1 <sup>st</sup>	2021 06 - 2023 12
<i>NAFCC Regional Federation</i>				
N. Lepage	Representative	CA	2 <sup>nd</sup>	2021 06 - 2023 12

### 16.3.3. List of Addresses

#### **Chair**

##### **Prof. Leslie LAI**

Suite 7.09

MOB, Gleneagles Intan Medical Centre

282 Jalan Ampang 50450 Kuala Lumpur - MY

E-mail: Lesliecharleslai@gmail.com

#### **Past Chair**

##### **Dr. Graham H BEASTALL**

'Laboratory Medicine Consulting'

Mayfield, Birdston, Kirkintilloch

Glasgow G66 1RW UK

E-mail: gbeastall@googlemail.com

#### **AFCB Regional Federation Representative**

##### **Dr. Osama Najjar**

General Director

Allied Health Professions Ministry of Health (MOH)

Palestine

E-mail: doctor91@hotmail.com

#### **AFCC Regional Federation Representative**

##### **Dr. Angela AMAYO**

University of Nairobi

P.O. Box 19434 00202 - KNH Nairobi - Kenya

E-mail: aamayo2@gmail.com; angela.amayo@uonbi.ac.ke

#### **APFCB Regional Federation Representative**

##### **Dr. Endang HOYARANDA**

Prodia Clinical Laboratory - Prodia Group

Kramat Raya 150 - Jakarta 104030 - Indonesia

E-mail: endang.hoyaranda@prodia.co.id

### **COLABIOCLI Regional Federation Representative**

#### **Dr. Rosa SIERRA-AMOR**

LAQUIMS, S.C. Clinical Laboratory  
Veracruz 91700 - Mexico  
Email: rosa.sierra.amor@gmail.com

### **EFLM Regional Federation Representative**

#### **Prof. Klaus P. KOHSE**

School of Medicine and Health Sciences  
Carl von Ossietzky University of Oldenburg (Germany)  
Kurt-Schumacher-Str. 18 - 26131 Oldenburg - Germany  
Email: Klaus.peter.kohse@uol.de

### **NAFCC Regional Federation Representative**

#### **Dr. Nathalie LEPAGE**

Laboratory Head, Inherited Metabolic Diseases- Newborn Screening Ontario  
415 Smyth Road - Ottawa, ON, K1H 8M8 - Canada  
E-mail: nlepage@cheo.on.ca

## **16.4. Annual Report**

The IFCC Annual Report is an important document. It is prepared at the beginning of each calendar year as a summary of the past year's activities. It is compiled by the Secretary of IFCC from the reports of the respective IFCC Officers, National Societies and Regional Federations. The IFCC Annual Report gives National Societies an opportunity to report their activities to other member societies. These reports are a part of the IFCC Annual Report, which is available in the IFCC website [www.ifcc.org](http://www.ifcc.org). The IFCC Annual Report is also published in Lab Medica International as a short version without the reports of the National Societies.

## **16.5. IFCC Handbook**

The production of the IFCC Handbook occurs once every three years and coincides with the term of the Executive Board. It is available from the IFCC website ([www.ifcc.org](http://www.ifcc.org)). The Handbook gives all the information about the operations and activities of IFCC.

The Handbook includes a section on the organisation of IFCC, its aims and strategic objectives over the three-year term of the Executive Board. The Handbook lists IFCC Regional Organizations, Divisions, Committees, Working Groups and Task Forces, IFCC programmes and projects. The Full Members, Corporate Members and Affiliate Members are also included with the names and addresses of their contact persons. The Statutes and Rules of the IFCC are the basis of its operations and they are also published in the Handbook. The Handbook is intended to give basic information on IFCC and its operation and to help readers to find contacts with laboratory experts involved in IFCC activities.

## **16.6. IFCC Procedures Manual**

The IFCC Procedure Manual is a document which details the procedures for all the IFCC activities. It helps new IFCC officials learn about how IFCC operates. This document is available for the IFCC officers only.

## 16.7. Project Proposal Forms

Proposals for new projects must be submitted on a Project Proposal Form that can be requested to the IFCC Office (ifcc@ifcc.org)

## 16.8. IFCC Numbering System

The IFCC uses a numerical system for all its official correspondence. This numbering system is also used for storing and archiving IFCC records. The numbering system is continually updated with new activities. The system at the time of preparing this Handbook was as follows.

### 1. Minutes of EB meetings

#### 1.1. Minutes

- 1.1.80. Rabat 2000
- 1.1.81. Captiva Island 2000
- 1.1.82. Dubrovnik 2001
- 1.1.83. Prague 2001
- 1.1.84. Milano 2001
- 1.1.85. Vienna 2002
- 1.1.86. Orlando 2002
- 1.1.87. Kyoto 2002
- 1.1.88. Vienna 2003
- 1.1.89. Barcelona 2003
- 1.1.90. Milano 2003
- 1.1.91. Sousse 2004
- 1.1.92. Perth 2004
- 1.1.93. Milano 2004
- 1.1.94. Vienna 2005
- 1.1.95. Orlando 2005
- 1.1.96. Milano 2005
- 1.1.97. Paraguay 2006
- 1.1.98. Chicago 2006
- 1.1.99. Milano 2006
- 1.1.100. Washington 2007
- 1.1.101. Amsterdam 2007
- 1.1.102. Beijing 2007
- 1.1.103. Antalya 2008
- 1.1.104. Fortaleza 2008
- 1.1.105. Milano 2008
- 1.1.106. Windsor 2009
- 1.1.107. Milano 2009
- 1.1.108. Innsbruck 2009
- 1.1.109. Milano 2009
- 1.1.110. Corfu 2010
- 1.1.111. Seoul 2010
- 1.1.112. Paris 2011
- 1.1.113. Berlin 2011
- 1.1.114. Milano 2011
- 1.1.115. Milano 2012
- 1.1.116. Windsor 2012
- 1.1.117. Marrakech 2012

- 1.1.118. Kuala Lumpur 2012
- 1.1.119. Buenos Aires 2013
- 1.1.120. Milano 2013
- 1.1.121. Bali 2013
- 1.1.122. Washington 2014
- 1.1.123. Istanbul 2014
- 1.1.124. Rome 2014
- 1.1.125. Milan 2015
- 1.1.126. Paris 2015
- 1.1.127. Quito 2015
- 1.1.128. Madrid 2016
- 1.1.129. Philadelphia 2016
- 1.1.130. Taipei 2016
- 1.1.131. Milano 2017
- 1.1.132. Athens 2017
- 1.1.133. Durban 2017
- 1.1.134. Milano 2018
- 1.1.135. Rome 2018
- 1.1.136. Budapest 2018
- 1.1.137. Tunis 2019
- 1.1.138. Barcelona 2019
- 1.1.139. Jaipur 2019
- 1.1.140. Milan 2020
- 1.1.141. Conference Call March-April 2020
- 1.1.142. Conference Call April 2020
- 1.1.143. Conference Call May 2020
- 1.1.144. Conference Call June 2020
- 1.1.145. Conference Call July 2020
- 1.1.146. Conference Call September 2020
- 1.1.147. Conference Call October 2020
- 1.1.148. Conference Call November-December 2020
- 1.1.149. Conference Call January 2021
- 1.1.150. Conference Call February 2021
- 1.1.151. Conference Call March 2021
- 1.1.152. Conference Call April 2021
- 1.1.153. Conference Call May 2021
- 1.1.154. Conference Call June 2021
- 1.1.155. Conference Call July 2021

## 2. Full Members

### 2.1. Member Societies

- 2.1.2. Argentina
- 2.1.3. Australia and New Zealand
- 2.1.4. Austria
- 2.1.5. Belgium
- 2.1.6. Brazil
- 2.1.7. Bulgaria
- 2.1.8. Canada
- 2.1.9. Chile
- 2.1.10. Colombia
- 2.1.11. Albania

- 2.1.12. Denmark
- 2.1.13. Ecuador
- 2.1.14. Egypt
- 2.1.15. Germany
- 2.1.16. Finland
- 2.1.17. France
- 2.1.19. Hungary
- 2.1.20. Iran
- 2.1.21. Ireland
- 2.1.22. Israel
- 2.1.23. Italy
- 2.1.25. Japan
- 2.1.26. Kenya
- 2.1.27. Luxembourg
- 2.1.29. Morocco
- 2.1.30. Netherlands
- 2.1.31. Croatia
- 2.1.32. Nigeria
- 2.1.33. Norway
- 2.1.34. Poland
- 2.1.36. Singapore
- 2.1.37. South Africa
- 2.1.38. Spain
- 2.1.39. Sweden
- 2.1.40. Switzerland
- 2.1.41. Syria
- 2.1.43. United Kingdom
- 2.1.44. United States
- 2.1.46. Serbia
- 2.1.47. Indonesia
- 2.1.49. Hong Kong
- 2.1.50. China - Taipei
- 2.1.51. Iceland
- 2.1.52. Korea
- 2.1.54. Vietnam
- 2.1.55. India
- 2.1.56. Cuba
- 2.1.57. Tunisia
- 2.1.58. Czech Republic
- 2.1.59. Slovak Republic
- 2.1.60. Guatemala
- 2.1.61. Latvia
- 2.1.62. Slovenia
- 2.1.63. Thailand
- 2.1.64. Greece
- 2.1.66. Paraguay
- 2.1.67. Jordan
- 2.1.68. Russia
- 2.1.69. Uruguay
- 2.1.70. Lithuania
- 2.1.71. Romania \*
- 2.1.72. Turkey



- 2.1.73. Malaysia
- 2.1.75. China - Beijing
- 2.1.76. Dominican Republic
- 3.1.77. Lebanon
- 2.1.80. Estonia
- 2.1.82. Portugal
- 2.1.83. Pakistan
- 2.1.84. Bosnia Herzegovina
- 2.1.85. Cyprus
- 2.1.86. Montenegro
- 2.1.87. Sri Lanka
- 2.1.88. Ukraine\*\*
- 2.1.89. Sudan
- 2.1.91. Ethiopia
- 2.1.92. Philippines
- 2.1.93. Algeria
- 2.1.94. Nepal
- 2.1.95. Zimbabwe
- 2.1.96. Kazakhstan
- 2.1.97. Zambia
- 2.1.98. Bolivia
- 2.1.99. Mexico
- 2.1.100. Macedonia
- 2.1.101. Saudi Arabia
- 2.1.102. Malawi
- 2.1.103. Kosovo
- 2.1.105. Palestine
- 2.1.106. Panama
- 2.1.107. Georgia
- 2.1.108. Iraq
- 2.1.109. Myanmar
- 2.1.110. Peru

## **2.2 Applications**

## **2.3 Withdrawal - Suspended Members**

- 2.1.78. Honduras
- 2.1.90. Peru
- 2.1.104. Belarus

## **2.4. Annual Dues**

## **2.9. Ballots for Membership**

## **3. Corporate Members**

### **3.1. Current Members**

- 3.1.1. Abbott
- 3.1.2. Asahi Kasei Pharma Corporation
- 3.1.6. Beckman Coulter, Inc.
- 3.1.13. DiaSys Diagnostic Systems GmbH
- 3.1.15. Sekisui Diagnostics (UK) Ltd.
- 3.1.21. Ortho-Clinical Diagnostics, Inc.

- 3.1.29. Radiometer Medical ApS
- 3.1.30. Randox Laboratories Ltd.
- 3.1.31. Roche Diagnostics
- 3.1.34. Sebia S.A.
- 3.1.36. Fujifilm Wako Pure Chemical Corporation
- 3.1.45. Thermo Fisher Scientific
- 3.1.48. HyTest Ltd.
- 3.1.53. A. Menarini Diagnostics
- 3.1.54. Sysmex Europe GmbH
- 3.1.55. BD Life Sciences – Preanalytical Systems
- 3.1.57. Bio-Rad Laboratories
- 3.1.58. Mitsubishi Chemical Europe GmbH
- 3.1.61. The Binding Site Group, Ltd.
- 3.1.66. Siemens Healthcare Diagnostics
- 3.1.68. Gentian AS
- 3.1.69. Sentinel CH. Spa
- 3.1.70. Agappe Diagnostics Ltd.
- 3.1.71. Maccura Biotechnology Co., Ltd.
- 3.1.77. Mindray - Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- 3.1.78. Nova Biomedical Corporation
- 3.1.81. C.P.M. Diagnostic Research SAS
- 3.1.82. Oneworld Accuracy Collaboration
- 3.1.83. Labor Dr. Wisplinghoff
- 3.1.88. Shanghai Zhicheng Biological Technology Co, Ltd
- 3.1.90. Snibe Co., Ltd
- 3.1.91. Fujirebio Europe
- 3.1.92. Diatron
- 3.1.95. Helena Biosciences Europe
- 3.1.96. MedicalSystem Biotechnology Co., Ltd.
- 3.1.97. Shanghai Kehua Bio-Engineering Co., Ltd.
- 3.1.99. Hemas Hospitals (PVT) Ltd.
- 3.1.101. ET Healthcare Inc.
- 3.1.102. Nittobo Medical Co. Ltd.
- 3.1.106. Labtronic
- 3.1.107. Tosoh Corporation
- 3.1.108. Wuhan Life Origin Biotech Joint Stock Co., Ltd. – Szybio
- 3.1.109. Megalab, JSC
- 3.1.110. LumiraDx
- 3.1.111. Shenzhen YHLO Biotech Co., Ltd
- 3.1.112. Technogenetics

## **3.2. Applications**

### **3.3. Withdrawals – Suspended Members**

- 3.1.86. PPD Inc.
- 3.1.89. ADx Neurosciences
- 3.1.60. Analis R&D Diag
- 3.1.93. Guangzhou Wondfo Biotech Co. Ltd.
- 3.1.98. Beijing Dream Diagnostics Medicine (DDM) Technology Co. Ltd.
- 3.1.100. Timedico A/S – Sarstaedt
- 3.1.103. SCL Healthcare
- 3.1.104. Agilent
- 3.1.105. Zhejiang Quark Biotechnology Co., Ltd

### **3.4. Annual Dues**

### **3.5. Guidelines and Rules**

### **3.40. Other Business**

## **4. Affiliated Members**

### **4.1. Current Members**

- 4.1.1. Asociación Española de Farmacéuticos Analistas (AEFA)
- 4.1.5. Sociedade Brasileira de Patologia Clínica / Medicina Laboratorial (SBPC/ML)
- 4.1.9. Philippine Council for Quality Assurance in Clinical Laboratories (PCQACL)
- 4.1.11. Association of Medical Biochemists of India (AMBI)
- 4.1.12. Federación Nacional de Químicos Clínicos (CONAQUIC A.C.)
- 4.1.13. Society of Clinical Biochemistry Specialists (KBUD) - Turkey
- 4.1.14. Iranian Association of Clinical Laboratory Doctors
- 4.1.15. Nepalese Association for Clinical Chemistry (NACC)
- 4.1.16. Society for Medical Technology & Laboratories - Jordan
- 4.1.17. Association for Quality Assurance of Laboratory Medicine – AQALM – Ukraine
- 4.1.18. Lab Medicine Committee, China Association of Medical Equipment
- 4.1.19. Egyptian Association of Healthcare Quality and Patient Safety
- 4.1.20. Kazakhstan Public Association - Federation of Laboratory Medicine (FLM)
- 4.1.21. French National Network of accredited Laboratories of Medical Biology (LABAC)
- 4.1.22. Serbian Society for Clinical Laboratory Medicine and Science (SCLM)
- 4.1.23. Sociedad Andaluza de Análisis Clínicos (SANAC)
- 4.1.24. Order of the Biochemists, Biologists, Chemists in Romanian Health System (OBBCSSR)
- 4.1.25. College of Chemical Pathologists of Sri Lanka (CCPSL)

### **4.2. Applications**

### **4.3. Withdrawals - Suspended Members**

- 4.1.3. Regional Association for Clinical Laboratory Diagnosis, St. Petersburg

### **4.4. Annual Dues**

### **4.40. Other Business**

## **5. Organizations (Regional) Affiliated with IFCC**

### **5.1. Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB)**

### **5.2. Latin American Confederation of Clinical Biochemistry (COLABIOCLI)**

### **5.4. European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)**

### **5.5. Arab Federation of Clinical Biology (AFCB)**

- 5.6. African Federation of Clinical Chemistry (AFCC)**
- 5.7. North American Federation of Clinical Chemistry (NAFCC)**
- 5.40. Other Business**

## **6. International/Regional Organisations**

- 6.1 World Health Organisation (WHO)**
  - 6.1.1. Special Programme of Research, Development and Research Training in Human Reproduction (HRP)
  - 6.1.2. WHO Regional Office for Europe
  - 6.1.3. Pan American Health Organization (PAHO)
- 6.2. Clinical Laboratory Standards Institute (CLSI) (formerly NCCLS)**
- 6.3. United Nations Organization (UN)**
- 6.4. International Union of Pure and Applied Chemistry (IUPAC)**
- 6.6. International Union of Immunological societies (IUIS)**
- 6.7. International Union of Biochemistry and Molecular Biology (IUBMB)**
- 6.8. Council of International Organisations of Medical Sciences (CIOMS)**
- 6.9. World Medical Association (WMA)**
- 6.10. International Society for Haematology (ISH)**
  - 6.10.1. International Committee for Standardization in Haematology (ICSH)
- 6.11. International Council for Science (ICSU)**
- 6.12. International Pharmaceutical Federation (FIP)**
- 6.13. World Association of Societies of Pathology and Laboratory Medicine (WASPALM)**
- 6.14. International Union of Basic and Clinical Pharmacology (IUPHAR)**
- 6.15. International Organization of Legal Metrology (OIML)**
- 6.18. Asian Pacific Committee for Clinical Laboratory Standards (APCCLS)**
- 6.22. Bureau International des Poids et Mesures (BIPM)**
- 6.23. International Standards Organization (ISO)**
  - 6.23.1. Technical Advisory Groups (ISO-TAG)
  - 6.23.2. Committee on Reference Materials (ISO-REMCO)
  - 6.23.3. Forum for Inter-Organisational Cooperation in Metrology (FICOM)
- 6.26. Japanese Committee for Clinical Laboratory Standards (JCCLS)**
- 6.30. European Committee for Standardization (CEN)**
- 6.31. European Commission Joint Research Centre (EC-JRC)**
- 6.33. National Institute for Biological standards and Control (NIBSC)**
- 6.37. National Institute of Standards (NIST)**
- 6.38. International Consortium for Harmonization of Clinical Laboratory Results (ICHCLR)**

**6.39. International Society on Thrombosis and Haemostasis**

**6.40. International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)**

**7. Congresses and Conferences Committee**

**7.1. Congresses and Conferences Executive Committee**

- 7.1.1. Mission Statement
- 7.1.2. Strategy
- 7.1.3. Projects

**7.2. International Congresses of Clinical Chemistry and Laboratory Medicine (ICCLM)**

- 7.2.1. 1954 - Amsterdam
- 7.2.2. 1956 - New York
- 7.2.3. 1957 - Stockholm
- 7.2.4. 1960 - Edinburgh
- 7.2.5. 1963 - Detroit
- 7.2.6. 1966 - Munich
- 7.2.7. 1969 - Geneva
- 7.2.8. 1972 - Copenhagen
- 7.2.9. 1975 - Toronto
- 7.2.10. 1978 - Mexico City
- 7.2.11. 1981 - Vienna
- 7.2.12. 1984 - Rio de Janeiro
- 7.2.13. 1987 - Den Hague
- 7.2.14. 1990 - San Francisco
- 7.2.15. 1993 - Melbourne
- 7.2.16. 1996 - London
- 7.2.17. 1999 - Florence
- 7.2.18. 2002 - Kyoto
- 7.2.19. 2005 - Orlando
- 7.2.20. 2008 - Fortaleza
- 7.2.21. 2011 - Berlin
- 7.2.22. 2014 - Istanbul
- 7.2.23. 2017 - Durban
- 7.2.24. 2020 - Seoul
- 7.2.25. 2023 - Rome

**7.3. Regional Congresses of Clinical Chemistry and Laboratory Medicine**

**7.3.1. Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB)**

- 7. 1995 - Bangkok
- 8. 1998 - Kuala Lumpur
- 9. 2001 - New Delhi
- 10. 2004 - Perth
- 11. 2007 - Beijing
- 12. 2010 - Seoul
- 13. 2013 - Bali
- 14. 2016 - Taipei
- 15. 2019 - Jaipur
- 16. 2022 - Seoul

**7.3.2. European Federation of Clinical Chemistry and Laboratory**

#### **Medicine (EFLM)**

11. 1995 - Tampere
12. 1997 - Basel
13. 1999 - Florence
14. 2001 - Prague
15. 2003 - Barcelona
16. 2005 - Glasgow
17. 2007 - Amsterdam
18. 2009 - Innsbruck
19. 2011 - Berlin
20. 2013 - Milano
21. 2015 - Paris
22. 2017 - Athens
23. 2019 - Barcelona
24. 2021 - Munich
25. 2023 - Rome

#### **7.3.4. Latin American Confederation of Clinical Biochemistry (COLABIOCLI)**

12. 1995 - Buenos Aires
13. 1997 - Caracas
14. 1999 - Puerto Rico
15. 2001 - Florianopolis
16. 2003 - San José
17. 2005 - Asunción
18. 2008 - Panama
19. 2010 - Santiago del Chile
20. 2011 - Punta Cana
21. 2013 - Lima
22. 2015 - Quito
23. 2017 - Punta del Este
24. 2019 - Panama
25. 2022 - Leon

#### **7.3.6. Arab Federation of Clinical Biology (AFCB)**

9. 2000 - Rabat
10. 2004 - Monastir
11. 2006 - Damascus
12. 2009 - Beirut
13. 2012 - Marrakech
14. 2015 - Khartoum
15. 2018 - Palestine
16. 2021 - Beirut

#### **7.3.7. African Federation of Clinical Chemistry (AFCC)**

1. 2009 - Ibadan
2. 2011 - Nairobi
3. 2013 - Cape Town
4. 2015 - Harare
5. 2017 - Durban
6. 2019 - Harare
7. 2021 - Lusaka

### **7.4. IFCC Specialised Conferences**

#### **7.4.1. Roche Bergmeyer Conferences**

1. 1988 - Principles of Assays in Medical Sciences
2. 1989 - Laboratory Measurements in Lipid Disorders
3. 1990 - Immunoassay Standardisation
4. 1992 - Two Immunoassay Reference Systems: Cortisol and Human Chorionic Gonadotrophin
5. 1994 - Tumor Markers: Current Status and Future Trends
6. 1996 - Biochemical Markers for Bone Diseases: Current Status and Future Trends
7. 1999 - Biochemical Markers for Myocardial damage: Current Status and Future Trends
8. 2001 - Biochemical Markers for Autoimmune Diseases: Current Status and Future Trends
9. 2003 - Nucleic Acid Markers for Bacterial and Viral Infections in Intensive Care and Immunocompromised Patients
10. 2005 - Diabetes Mellitus & Cardiovascular Disease
11. 2008 - Markers of Kidney Disease
12. 2010 - Novel biomarkers: From Discovery to Clinical Application
13. 2012 - Vitamin D in Health and Disease
14. 2014 - Women's Health
15. 2016 - Biomarkers in the Diagnosis and Monitoring of Cancer

#### **7.4.2 European Beckman Coulter Molecular Basis of Diseases**

1. 1998 - Inflammatory Diseases
2. 2000 - Cell Biology of Neuronal Dysfunction

#### **7.4.3. Roche Molecular Biology**

1. 1998 - Recent Progress in Molecular Biology Technology
2. 2000 - Validating and Using Pharmacogenetics

#### **7.4.5 Beckman Coulter Proteins**

1. 2001 - Prague
2. 2003 - Barcelona

#### **7.4.6. Ortho Clinical Diagnostics Conference**

1. 2008 - Birmingham - Biochemical markers in clinical cardiology: perspectives from present to future
2. 2011 - Paris - Pregnancy-related disorders

#### **7.4.7. Siemens Conference**

1. 2014 - Toronto - Biomarkers in Neuropsychiatric Disorders

#### **7.4.8. Roche Conference**

1. 2014 - Rome - Biomarkers in Alzheimer Disease
2. 2016 - Mexico City - Biomarkers in Alzheimer Disease

#### **7.4.9. Mediterranean Conference.**

1. 2018 - Rome - 1<sup>st</sup> IFCC EFLMAFCB Conference – Laboratory Medicine meeting the needs of Mediterranean Nations.

#### **7.4.10. Critical Role of Clinical Laboratories in the COVID-19 Pandemic**

1. 2021 - Virtual IFCC Global Conference on COVID-19

- 7.5. Congress Guidelines**
- 7.8. Congresses with IFCC Auspices**
- 7.9. IFCC General Conference**
- 7.20. Membership**
- 7.30. Budget**
- 7.40. Other Business**

## **8. Scientific Division**

### **8.1. Scientific Division Executive Committee**

- 8.1.1. Mission Statement
- 8.1.2. Strategy
- 8.1.3. Projects
- 8.1.4. Terms of Reference

### **8.2. Committees**

- 8.2.6. Nomenclature, Properties and Units (C-NPU)
- 8.2.11. Molecular Diagnostics (C-MD)
- 8.2.23. Traceability in Laboratory Medicine (C-TLM)
- 8.2.24. Reference Intervals and Decision Limits (C-RIDL)
- 8.2.25. Standardization of Thyroid Function Tests (C-STFT)
- 8.2.26. Harmonization of Autoimmune Tests (C-HAT)
- 8.2.27. Bone Metabolism (C-BM)

### **8.3. Working Groups**

- 8.3.35. Standardisation of Hemoglobin A2 (WG-HbA2)
- 8.3.36. Carbohydrate-Deficient Transferrin (WG-CDT)
- 8.3.39. Standardisation of Albumin Assay in Urine (WG-SAU)
- 8.3.40. Standardisation of Pregnancy-Associated Plasma Protein A (WG-PAPPA)
- 8.3.41. Growth Hormone (WG-GH)
- 8.3.42. Standardisation of Insulin Assays (WG-SIA)
- 8.3.43. Standardisation of Troponin I (WG-TNI)
- 8.3.46. Growth Hormone (WG-GH)
- 8.3.49. CSF Protein (WG-CSF)
- 8.3.51. Commutability (WG-C)
- 8.3.53. Immunosuppressive Drugs (WG-ID)
- 8.3.54. Apolipoproteins by Mass Spectrometry (WG-APO MS)
- 8.3.55. Pancreatic Enzymes (WG-PE)
- 8.3.56. Fecal Immunochemical Testing (WG-FIT)
- 8.3.57. Cell free DNA and related circulating biomarkers (WG-cfDNA)
- 8.3.58. Standardization of Procalcitonin assays (WG-PCT)
- 8.3.60. Continuous Glucose Monitoring (WG-CGM)
- 8.3.61. Development of a Reference Measurement System for sustainable PT/INR Standardisation (WG-PT/INR)

### **8.4. WHO collaboration**

### **8.5. General Rules of Procedure**



- 8.6. Documents**
- 8.8. Project Proposals**
- 8.9. Position Paper**
- 8.12. Reference Materials & Standardisation**
- 8.13. Joint Committee for Guides in Metrology (JCGM)**
  - 8.13.1. WG 1: Reference-Measurements and Reference-Materials
  - 8.13.2. WG 2: Reference Laboratories (JCGM VIM-GUM)
- 8.14. Joint Committee for Traceability in Laboratory Medicine (JCTLM)**
- 8.15. SD Aspects of IFCC Specialised Conferences**
- 8.16. AACC Harmonisation Project**
- 8.19. Meetings**
- 8.20. Membership**
- 8.25. Agenda/Minutes**
- 8.26. Activity and Annual Report**
- 8.30. Budget**
- 8.31. Contingency Fund**
- 8.40. Other Business**

## **9. Education and Management Division**

### **9.1. Education and Management Division Executive**

- 9.1.1. Mission Statement
- 9.1.2. Strategy
- 9.1.3. Projects
- 9.1.4. Terms of Reference

### **9.2. Committees**

- 9.2.4. Clinical Molecular Biology Curriculum (C-CMBC)
- 9.2.7. Evidence Based on Laboratory Medicine (C-EBLM)
- 9.2.9. Clinical Laboratory Management (C-CLM)
- 9.2.11. Education in the Use of Biomarkers in Diabetes (C-EUBD)
- 9.2.12. Cardiac Biomarkers (C-CB)
- 9.2.13. Chronic Kidney Disease (C-CKD)
- 9.2.14. Point of Care Testing (C-POCT)
- 9.2.16. Value Proposition for Laboratory Medicine (C-VPLM)

### **9.3. Working Groups**

- 9.3.8. Laboratory Errors and Patient Safety (WG-LEPS)
- 9.3.11. Personal Support (WG-PS)

### **9.4. Special Projects**

- 9.4.1. Visiting Lecture Program (VLP)
- 9.4.2. Flow Cytometry (WG-FC)

### **9.5. General Rules of Procedure**

### **9.6. Documents**

- 9.8. Project Proposals**
- 9.19. Meetings**
- 9.20. Membership**
- 9.25. Agenda/Minutes**
- 9.26. Activity and Annual Reports**
- 9.30. Budget**
- 9.40. Other Business**
- 10. Communications and Publications Division**
  - 10.1. Communications and Publications Division Executive**
    - 10.1.1. Mission Statement
    - 10.1.2. Strategy
    - 10.1.4. Terms of Reference
  - 10.2. Committees**
    - 10.2.1. Public Relation (C-PR)
    - 10.2.2. Internet and eLearning (C-IeL)
  - 10.3. Working Groups**
    - 10.3.1. Electronic Journal of IFCC (WG-eJIFCC)
    - 10.3.2. IFCC e-News (WG-IFCC News)
    - 10.3.4. Ibero-American Nomenclature and Translation (WG-IANT)
  - 10.4. Publication of Recommendations and Documents**
  - 10.5. General Rules of Procedure**
    - 10.5.1. IFCC Procedure Manual
    - 10.5.2. Individual Responsibilities for Preparation of an IFCC Document
    - 10.5.3. Instructions to authors to eJIFCC
  - 10.6. Publications**
    - 10.6.1. Preparation of Documents of Committees and Working Groups
    - 10.6.2. Monographs
    - 10.6.3. Books
    - 10.6.4. Conference proceedings
    - 10.6.5. Annual report
    - 10.6.6. Handbook
    - 10.6.8. Views and Reviews
    - 10.6.10. Electronic Publications
    - 10.6.20. Other publications
  - 10.7. Web Site**
    - 10.7.1. Organisational matters
    - 10.7.2. Bookstore
    - 10.7.3. eBanners
    - 10.7.4. Databases
    - 10.7.5. Distance Learning Programs
  - 10.8. Related Journals**
    - 10.8.1. Meetings of Editors
    - 10.8.2. Journals
      - 10.8.2.1 Clinical Chemistry and Laboratory Medicine (CCLM)

- 10.8.2.2 Clinica Chimica Acta (CCA)
- 10.8.2.3 Labmedica International (LMI)
- 10.8.2.5 Annals of Clinical Biochemistry (ACB)

#### **10.9. Public Relations**

- 10.9.1. Brochure
- 10.9.2. IFCC Booth
- 10.9.3. Posters
- 10.9.4. Publicity
- 10.9.5. Miscellaneous PR Projects

#### **10.10. Corporate Member Activities**

#### **10.19. Meetings**

#### **10.20. Membership**

#### **10.25. Agenda/Minutes**

#### **10.26. Activity and Annual Report**

- 10.26.1. Report of the Chair
- 10.26.2. Report of the Vice Chair
- 10.26.3. Report of the Secretary

#### **10.30. Budget**

#### **10.40. Other Business**

### **11. Emerging Technologies Division**

#### **11.1 Emerging Technologies Division Executive**

- 11.1.1. Mission Statement
- 11.1.2. Strategy
- 11.1.4. Terms of Reference

#### **11.2. Committees**

- 11.2.1. Committee for Emerging Pediatric Laboratory Medicine (C-EPLM)
- 11.2.2. Committee on Mobile Health and Bioengineering in Laboratory Medicine (C-MHBLM)
- 11.2.3. Committee for Omics Translation (C-OT)

#### **11.3. Working Groups**

- 11.3.1. Guidance for the implementation of custom-made genomic panels (WG-CGP)
- 11.3.2. Volatolomics (WG-Vol)
- 11.3.3. Artificial Intelligence and Genomic Diagnostics (WG-AIGD)
- 11.3.4. Single Cell and Spatial Transcriptomics (WG-SCST)

#### **11.5. General Rules of Procedure**

#### **11.6. Documents**

#### **11.8. Project Proposals**

#### **11.19. Meetings**

#### **11.20. Membership**

#### **11.25. Agenda/Minutes**

#### **11.26. Activity and Annual Reports**

### 11.30. Budget

### 11.40. Other Business

## 12. Awards

### 12.1. Awards Committee

- 12.1.1. IFCC Distinguished Clinical Chemist Award
  1. 1969 DD van Slyke (US)
  2. 1972 CP Stewart (UK)
  3. 1975 L Eldjarn (NO)
  4. 1978 CB Laurell (SE)
  5. 1981 P Metais (FR)
  6. 1984 P Astrup (DK)
  7. 1987 HU Bergmeyer (DE)
  8. 1990 NG Anderson (US)
  9. 1993 R Ekins (UK)
  10. 1996 M Wilchek (IL)
  11. 1999 DW Moss (UK)
  12. 2002 N Hales (UK)
  13. 2005 G Siest (FR)
  14. 2008 DS Young (US)
  15. 2011 UH Stenman (FI)
  16. 2014 MJ McQueen (CA)
  17. 2017 DYM Lo (HK)
  18. 2020 N Rifai (US)
- 12.1.2. IFCC Distinguished International Service Award (1981-1987), since 1990 IFCC Henry Wishinsky Award for Distinguished International Service
  1. 1981 M Rubin (US)
  2. 1984 P Lous (DK)
  3. 1987 TP Whithead (UK)
  4. 1990 ML Castillo de Sanchez (MX)
  5. 1993 R Dybkaer (DK)
  6. 1996 N Tietz (US)
  7. 1999 M Shaarawy (Egypt)
  8. 2002 O Zinder (IL)
  9. 2005 JH Ladenson (US)
  10. 2008 D Burnett (UK)
  11. 2011 C Burtis (US)
  12. 2014 R Dufour (US)
  13. 2017 J. Hicks (US)
  14. 2020 G. Shannan (SY)
- 12.1.3. IFCC Award for Distinguished Contributions in Education
  1. 1999 L Thomas (DE)
  2. 2002 JB Henry (US)
  3. 2005 WJ Marshall (UK)
  4. 2008 NW Tietz (US)
  5. 2011 M Burritt (US)
  6. 2014 CA Burtis (US)
  7. 2017 N Rifai (US)
  8. 2020 T. Annesley (US)
- 12.1.4. IFCC Abbott Award for Significant Contributions to Molecular Diagnostics

1. 2002 L Peltonen (US)
  2. 2003 R Bertina & P Reitsma (NL)
  3. 2004 M Ferrari (IT)
  4. 2005 CT Wittwer (US)
  5. 2006 D Lo (HK)
  6. 2008 O Kallioniemi (FI)
  7. 2009 EP Diamandis (CA)
  8. 2010 G Tsongalis (US)
  9. 2011 M Neumaier (DE)
  10. 2014 F Barany (US)
  11. 2017 S. Branford (AU)
  12. 2020 A. Ferreira-Gonzalez (US)
- 12.1.5. Distinguished Award for Laboratory Medicine and Patient Care
1. 2008 CWK Lam (HK)
  2. 2011 RAJ Wanders (NL)
  3. 2014 M Plebani (IT)
  4. 2017 E. Diamandis (CA)
  5. 2020 D. Sacks (US)
- 12.1.6. IFCC Robert Schaffer Award for Outstanding Achievements in the Development of Standards for Use in Laboratory Medicine
1. 2008 L Siekmann (DE)
  2. 2011 L Thienpont (BE)
  3. 2014 WG Miller (US)
  4. 2017 M.M. Müller (AT)
  5. 2020 G. Myers (US)
- 12.1.7. IFCC Young Investigator Award
1. 2011 R Chiu (HK)
  2. 2014 G Baird (US)
  3. 2017 R. Shrestha (NP)
  4. 2020 L.S. Eberlin (US)
- 12.1.8. IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics
1. 2017 J.H. Ladenson (US)
  2. 2020 F. Apple (US)
- 12.1.9. Gérard Siest-Biologie Prospective Award
1. 2020 J.B. Woillard (FR)
- 12.1.10. IFCC Distinguished Women Scientist Award for Contribution to In-Vitro Diagnostics
1. 2020 S. Quijano (CO)

## 13. Special Projects and Task Forces

### 13.1. Task Forces

- 13.1.1 Task Force on Ethics (TF-E)
- 13.1.6 Task Force for Young Scientists (TF-YS)
- 13.1.12 Task Force on History (TF-H)
- 13.1.15 Task Force Corporate Members (TF-CM)
- 13.1.16 Task Force COVID-19
- 13.1.17 Task Force on Global Newborn Screening (TF-NBS)
- 13.1.18 Task Force on Global Lab Quality (TF-GLQ)
- 13.1.19 Taskforce on Outcome Studies in Lab Medicine (TF-OSLM)
- 13.1.20 Taskforce on Global Reference Interval Database (TF-GRID)
- 13.1.21 Taskforce on Global eLearning/eAcademy (TF-GEL)

## **13.2. IFCC Professional Exchange Programmes (PEP)**

13.2.1. Professional Scientific Exchange Programme (PSEP)

13.2.2. Professional Management Exchange Programme (PMEP)

## **13.3. IFCC Travel Scholarships**

## **14. IFCC Statutes and Rules**

### **14.1. Statutes**

### **14.2. Rules**

## **15. IFCC Finances**

### **15.1. Organization of Finances**

### **15.2. Budget**

### **15.3. Income and Expenditure**

15.3.1. Income

15.3.2. Expenditure

### **15.4. Annual Dues**

### **15.5. Guidelines for Industry Support**

### **15.6. Income from Congresses**

### **15.7. Financial Advisory Committee**

### **15.40. Other Business**

## **16. Organisational Matters**

### **16.1. IFCC Office**

### **16.3. Nominations Committee**

### **16.4. Annual Report**

### **16.5. IFCC Handbook**

### **16.6. IFCC Procedures Manual**

### **16.7. Project Proposal Forms**

### **16.8. IFCC Numbering System**

### **16.9. Letter from IFCC President**

### **16.10. Structure of IFCC**

### **16.11. IFCC Public Relations Project**

### **16.12. Statutes of IFCC Office**

### **16.13. Members Mailing Lists**

### **16.20. Intellectual Property**

### **16.40. Other Business**

## **17. Future Development**

### **17.6. Strategic Plan**

## 18. IFCC Foundation for Emerging Nations (FEN)

### 19. Meetings

#### 19.1. Council Meetings (General Assembly)

- 19.1.1. Amsterdam, 1954
- 19.1.2. New York, 1956
- 19.1.3. Stockholm, 1957
- 19.1.4. Edinburgh, 1960
- 19.1.5. Detroit, 1963
- 19.1.6. Munich, 1966
- 19.1.7. Geneva, 1969
- 19.1.8. Copenhagen, 1972
- 19.1.9. Toronto, 1975
- 19.1.10. Mexico City, 1978
- 19.1.11. Vienna, 1981
- 19.1.12. Rio de Janeiro, 1984
- 19.1.13. Den Hague, 1987
- 19.1.14. San Francisco, 1990
- 19.1.15. Melbourne, 1993
- 19.1.16. London, 1996
- 19.1.17. Florence, 1999
- 19.1.18. Kyoto, 2002
- 19.1.19. Orlando, 2005
- 19.1.20. Fortaleza, 2008
- 19.1.21. Berlin, 2011
- 19.1.22. Istanbul, 2014
- 19.1.23. Durban, 2017
- 19.1.24. Seoul 2020\*
- 19.1.25. Rome 2023

*\*postponed from 2020 due to COVID-19 pandemic*

#### 19.6. General Conferences

1. Copenhagen, 1981
2. Copenhagen, 1984
3. Monza, 1988
4. Pont-a-Mousson, 1992
5. Leipzig, 1995
6. Seville, 1998
7. Dubrovnik, 2001
8. Tunis-Sousse, 2004
9. Antalya, 2008
10. Corfu, 2010
12. Kuala Lumpur, 2012
13. Madrid, 2016
14. Budapest 2018

#### 19.8. EB Meetings & International Relationships

- 19.8.1. President's International Relationships

### 20. Inter-EB Correspondence

